Top

Published in:

01-10-2010 | Poster presentation

How can the prevalent round recall rate be reduced?

Authors: A Ramakrishnan, I Haigh, J Liston, BJG Dall, N Sharma

Published in: Breast Cancer Research | Special Issue 3/2010

Excerpt

The prevalent round recall rate is higher than the incident recall rate. Implementation of age extension will lead to two prevalent rounds and with this increased clinical and financial pressure on screening units. Any processes that help reduce the recall rate will be of benefit to screening units. …

Title: How can the prevalent round recall rate be reduced?
Authors: A Ramakrishnan
I Haigh
J Liston
BJG Dall
N Sharma
Publication date: 01-10-2010
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue Special Issue 3/2010
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr2697

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 3/2010

Seeding of tumour cells following breast biopsy: a literature review

Educational abstract

Does a second image-guided biopsy contribute to the management of B3 lesions?

Reduced breast biopsy rates with a combined high temporal and high spatial resolution MR imaging protocol at 3 Tesla

Educational abstract

Mammographic follow-up of patients after treatment for breast cancer: is 5 years enough?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer